TRX-214

N/A

Report date: 2025/06/19 11:38:45

Base Information

Drug NameTRX-214
Drug Alias NameTRX-214TRX-214-1002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Myeloid cell surface antigen CD33Eukaryotic peptide chain release factor GTP-binding subunit ERF3A degraders
TargetsMyeloid cell surface antigen CD33Eukaryotic peptide chain release factor GTP-binding subunit ERF3A
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTherapex Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTherapex Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A